Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors by Dmitriy Zamarin, Diwakar Davar, Adel Samson, Kevin J Harrington, Siddharth Sheth, Eric Tu, Mitesh J Borad, Grace K Dy, Evanthia Galanis, Fernanda Arnaldez, Sandip P Patel, Nicholas Durham, Benedito A Carneiro, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Kevin Laubscher

Get full text